Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1 with a Kd value of 7 nM for human ALK1. It has an inhibitory effect on TGF-beta and can be used to study hepatocellular carcinoma (HCC).
CAS Number:
[1463459-96-2]
Target:
TGF-beta/Smad|||ALK
* VAT and and shipping costs not included. Errors and price changes excepted